Orca Bio’s Post

According to Christine Ryan, MD, Dana-Farber Cancer Institute, and coauthors, "Anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted." Learn more: https://lnkd.in/ec2npeRy #MantleCellLymphoma #MCL #Oncology #OncologyNews #OncologyResearch

a couple of peaks under the hood @ALETABIOTHERAPEUTICS #2 A great discussion about AletaBio's therapeutic mission with @AyeshaRashid of Xtalks podcasts. We go deep into the Aleta's tech and specific programs in the context of CAR T cells, including B cell lymphoma, multiple myeloma, acute myeloid leukemia, Her2+ CNS mets, and pediatric CNS cancers. https://lnkd.in/eqX2vWP8

Clinical activity and tolerability were achieved with the novel HIF-2α inhibitor DFF332 in those with advanced clear cell renal cell carcinoma. American Society of Clinical Oncology (ASCO) https://lnkd.in/e4veANRQ #kicsm #cancer #oncology #ASCO24

Is chemotherapy free treatment of leukemia possible? - Dr. Satya Prakash Y. #AcutePromyelocyticLeukemia #ALL #Cancer #CARTCellTherapy #ChronicLymphocyticLeukemia #CLL #CML #DownSyndrome #HaematoOncology #OncoDaily #Oncology

This recent conference abstract goes into Durable Responses in Acute Lymphoblastic Leukemia Using Targeted Therapies Approved for Acute Myeloid Leukemia, read more ⬇️ https://lnkd.in/gyht9aAM #leukemia #ALL #AML #oncology #cancer #cancerjournal #medicaljournal #abstract

#PaperoftheDay: "What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types" https://lnkd.in/eYfXcaYm #cancerresearch #oncology #OA #MedEd

Results from a phase 2 trial indicated that the combination of #venetoclax, #azacitidine, and #homoharringtonine was well-tolerated and demonstrated promising efficacy among patients with R/R acute myeloid leukemia #AML. Learn more: https://lnkd.in/dsAsKy_j Southern Medical University #Oncology #OncologyNews #OncNews #OncologyResearch #OncologyLearningNetwork #CancerResearch

The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leukemia and high-risk myelodysplastic syndrome. #oncology #AML #MDS https://lnkd.in/e-fh2rwp

Une nouvelle revue systématique de la litterature publiée ce jour avec Drs Thomas Fierling et Quentin Ollivier. "Prostate cancer screening has not significantly reduced mortality. International guidelines strongly endorse shared decision-making to navigate risks, emphasizing its crucial role prior to prescribing a prostate-specific antigen test. This study aims to provide insight into the current role of shared decision-making in primary care for prostate cancer screening and suggest ways to improve the process" https://lnkd.in/dVMn5HPR

#transcript Dr. Juan Vera, CEO of Marker Therapeutics, a clinical-stage immuno-oncology company, is developing next-gen immunotherapy with a multi-tumor-specific T-cell platform to overcome limitations of current T-cell therapies with narrow target recognition. This approach recognizes multiple antigens within the tumor and helps prevent tumor resistance & adaptation. Marker is participating in the APOLLO trial testing this broad spectrum of target recognition in lymphoma patients who have relapsed after CAR-T CD19 therapy while also exploring acute myeloid leukemia & pancreatic cancer.   #MarkerTherapeutics #Oncology #AutologousCellTherapy #TCellTherapy #Lymphoma markertherapeutics.com https://lnkd.in/gr3CNNiS